Expanded Polytetrafluoroethylene Spacer for Nonpenetrating Deep Sclerectomy Combined with Cataract Surgery

Purpose

To compare the outcomes of nonpenetrating deep sclerectomy (NPDS) with and without an expanded polytetrafluoroethylene (e-PTFE) implant combined with phacoemulsification (PE).

Design

Interventional case series with concurrent control group.

Materials and methods

Patients with medically uncontrolled glaucoma underwent PE nonpenetrating deep sclerectomy (NPDS) and were consecutively divided into a study group receiving an e-PTFE implant and a control group undergoing PE-NPDS. Intraocular pressure (IOP), corrected distance visual acuity (CDVA), and the number of glaucoma medications at 1 day, 1 week, 1 month, 3 months, and 6 months were recorded.

Results

A total of 22 eyes of 16 patients underwent PE-NPDS, including 11 eyes receiving an e-PTFE implant and another 11 eyes with no implant. NPDS with spacer achieved successful results in all patients, including eight (72.7%) complete and three (27.3%) qualified success, 6 months, postoperatively. The corresponding values in the control group were 10 (90.9%) and 1 (9.1%), respectively. In the spacer group, mean IOP was decreased from 19.3 ± 2.8 at baseline to 12.1 ± 2.0 mm Hg at month 6 (p < 0.001). Corresponding values for the control group were 18.6 ± 3.4 and 10.6 ± 1.5 mm Hg, respectively (p < 0.001). Mean IOPs were comparable between the study groups at all time points. Implant exposure occurred in one of the patients in the study group. While the implant was extruded, the IOP was medically controlled.

Conclusion

Outcomes of PE-NPDS using an e-PTFE implant were comparable to the same surgery without a spacer in the short term. Larger studies with longer follow-ups are needed to determine the efficacy and safety of this new implant.

How to cite this article

Hajizadeh M, Meshksar A, Hassanpour K, et al. Expanded Polytetrafluoroethylene Spacer for Nonpenetrating Deep Sclerectomy Combined with Cataract Surgery. J Curr Glaucoma Pract 2024;18(2):51-56.

Scleral concave pool trabeculectomy combined phacoemulsification in primary open-angle glaucoma with cataract

Background

To investigate the safety and efficacy of scleral concave pool trabeculectomy (SCPT) combined phacoemulsification for eyes with coexisting cataract and primary open-angle glaucoma (POAG).

Methods

This was a retrospective, controlled, interventional pilot case series. Thirty patients (30 eyes) were diagnosed with coexisting cataract and POAG between May 2015 and April 2018. Fourteen eyes underwent SCPT combined phacoemulsification were set as the study group, and 16 eyes received conventional phacotrabeculectomy were set as the control group. All patients were followed up for at least 6 months. The preoperative to postoperative changes in IOP, glaucoma medication requirements, BCVA, blebs functions, and adverse events were recorded.

Results

The groups were matched for baseline age, BCVA, IOP and types of IOP-lowering medications (all P > 0.05). At 6-month visit, there were no significant difference between control and study group in the improvement of BCVA (0.22 ± 0.24 versus 0.18 ± 0.26, P = 0.718), reduction of IOP (− 11.21 ± 8.61 mmHg versus − 9.19 ± 9.18 mmHg, P = 0.540) and the number of eyes that needed IOP-lowering medications (2 versus 3, P = 0.743). At the last visit, the rate of forming functioning blebs was significantly different between the study and control groups, (92.9% versus 68.7% respectively, P = 0.007). In the study group, 5 eyes developed hypotony, and 1 eye showed limited choroidal detachment, whereas in the control group 1 eye developed malignant glaucoma. All adverse events were successfully managed.

Conclusion

The SCPT combined phacoemulsification seems to be a safe and effective alternative to conventional phacotrabeculectomy for patients with POAG and visually significant cataract in the short-term.